Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Biotechnology

Healthcare
$19.17 -1.71%

-$0.22 today

Market cap
$676.80M
Beta
1.08
P/E (TTM)
-36.5
EPS (TTM)
-$0.24
52W Low $7.59High $14.24

Volume 0.00M

Average 0.00M

FRX.TO Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Fennec Pharmaceuticals Inc.TSX: FRX.TO

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0. Over 3 fiscal years it compounded at -10.3% a year.

Context

  • Income tax expense amounted to 0.2% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$106K-71.0% YoY
LTMMar 2026
$0-100.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-71.0%——
3-year CAGR-10.3%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
106K USD
Year-over-year change
-71.0%
4-year CAGR
-0.9%

Income Tax Expense vs competitors

How FRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the 6th highest of 7, against a peer median of -17.4%.
  • Income tax expense amounts to 0.0% of revenue for FRX.TO, versus a peer median of 3.5%.
FRX.TO Competitors
Income Tax Expense for FRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TSND.TOTerrAscend Corp.LTM Mar 2026$29.02M USD+30.6%—11.1%
DR.TOMedical Facilities CorporationLTM Mar 2026$10.69M USD+267.5%-1.0%3.5%
PRN.TOProfound Medical Corp.LTM Mar 2026$234.65K USD—-3.7%1.3%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$28.82K USD+200.2%——
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$23K CAD-99.7%—0.0%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$0 USD-100.0%-10.3%0.0%
HBP.TOHelix BioPharma Corp.LTM Apr 2026-CA$43K CAD-65.4%——
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-CA$13.66M CAD-17878.9%—5.0%
Peer median (excluding FRX.TO) —-17.4%-2.3%3.5%

Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.54M21.25M47.54M44.64M
Cost of Revenue086K1.26M3.18M3.76M
Gross Profit01.45M19.99M44.35M40.88M
Gross Margin—94.4%94.1%93.3%91.6%
Research & Development4.98M3.53M56K307K254.38K
Selling, General & Admin12.24M20.51M32.71M41.48M46.91M
Operating Expenses17.22M24.04M32.76M41.79M47.22M
Depreciation & Amortization17.22M149K287K800K103K
EBITDA(17.19M)(22.74M)(12.65M)4.8M(7.45M)
EBITDA Margin—-1481.2%-59.5%10.1%-16.7%
Operating Income(17.22M)(22.59M)(12.77M)2.57M(6.35M)
Operating Margin—-1471.6%-60.1%5.4%-14.2%
Interest Income54K195K441K1.68M800.78K
Interest Expense126K978K3.39M4.07M2.18M
Other Income / Expenses(123K)(1.13M)(3.27M)(2.64M)(3.29M)
Income Before Tax(17.35M)(23.71M)(16.05M)(71K)(9.64M)
Pre-Tax Margin—-1544.9%-75.5%-0.1%-21.6%
Income Tax Expense110K147K0365K106K
Net Income(17.46M)(23.86M)(16.05M)(436K)(9.74M)
Net Margin—-1554.5%-75.5%-0.9%-21.8%
EPS (Basic)(0.67)(0.91)(0.60)(0.02)(0.34)
EPS (Diluted)(0.67)(0.91)(0.60)(0.02)(0.34)
Weighted Avg Shares25.89M26.28M26.57M21.8M28.58M
Weighted Avg Shares (Diluted)26.01M26.28M26.57M27.3M28.58M

Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$19.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.